BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q4 EPS of ($0.96), $0.09 worse than the analyst estimate of ($0.87). Revenue for the quarter came in at $1.75 million versus the consensus estimate of $4.55 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.